IGF-1 LR3 has been extensively studied in research contexts for muscle growth and hypertrophy, muscle wasting conditions, recovery from injury or exercise, body composition optimization, metabolic disorders, wound healing, neuroprotection, and anti-aging applications, though it remains an experimental compound without regulatory approval for human therapeutic use
Even if the product could be reclassified to make it available for sale in pharmacies, it could not be used more frequently than every 2 3 months, so reclassification to a Pharmacy medicine would not help those who require more frequent injections. and then they also state: Our current advice to private clinics administering vitamin B12 injections which are not licensed medicinal products intravenously for non-medicinal purposes is that we do not regard these to be medicines and that they fall outside of the remit of the MHRA
Splitting the dose into twice-weekly injections would alter these pharmacokinetic properties, potentially reducing peak concentrations and changing the overall exposure pattern that trials demonstrated as safe and effective
Why the Reta-3 Naming Convention
